Key statistics
On Thursday, Matinas BioPharma Holdings Inc (6LJ0:MUN) closed at 3.35, 8.36% above its 52-week low of 3.09, set on Sep 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 3.35 |
Low | 3.35 |
Bid | -- |
Offer | -- |
Previous close | 3.35 |
Average volume | -- |
---|---|
Shares outstanding | 5.02m |
Free float | 4.89m |
P/E (TTM) | -- |
Market cap | 4.51m USD |
EPS (TTM) | -5.10 USD |
Data delayed at least 15 minutes, as of Sep 26 2024 07:00 BST.
More ▼
Announcements
- Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
- Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
- Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
- Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
- Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
- New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
- Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
- Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
- Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
- In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
More ▼